Veru (FRA:FMW0) Total Liabilities: €7.18 Mil (As of Mar. 2026)


FRA:FMW0 Veru Inc FRA:FMW0
32 GF Score
Price €3.44
! 2 Warning Signs
View Full Analysis

What is Veru Total Liabilities?

Veru FRA:FMW0 32 Total Liabilities is €7.18 Mil as of Mar. 2026. GuruFocus rates FRA:FMW0 with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Veru's Total Liabilities for the quarter that ended in Mar. 2026 was €7.18 Mil.

Veru's quarterly Total Liabilities declined from Sep. 2025 (€9.80 Mil) to Dec. 2025 (€8.92 Mil) and declined from Dec. 2025 (€8.92 Mil) to Mar. 2026 (€7.18 Mil).

Veru's annual Total Liabilities declined from Sep. 2023 (€28.43 Mil) to Sep. 2024 (€25.32 Mil) and declined from Sep. 2024 (€25.32 Mil) to Sep. 2025 (€9.80 Mil).

Veru Total Liabilities Historical Data

* Premium members only.

The historical data trend for Veru's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru Total Liabilities Chart

Veru Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.98 53.09 28.43 25.32 9.80

Veru Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.75 10.39 9.80 8.92 7.18
FRA:FMW0
32GF Score
Veru Inc FRA:FMW0
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Veru's Total Liabilities for the fiscal year that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.633+(2.009+1.159
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.80

Total Liabilities=Total Assets (A: Sep. 2025 )-Total Equity (A: Sep. 2025 )
=25.42-15.62
=9.80

Veru's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.661+(1.784+0.732
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.18

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=37.267-30.09
=7.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €7.18 Mil mean?
Veru (FRA:FMW0) has a Total Liabilities of €7.18 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Veru and its competitors.
Is Veru's Total Liabilities too high?
Veru's current Total Liabilities is €7.18 Mil. Overall, Veru has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Veru's Total Liabilities compare to AURX and PDSB?
Veru's Total Liabilities of €7.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Veru and its competitors. Veru's current Total Liabilities is €7.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (FRA:FMW0) has a current Total Liabilities of €7.18 Mil. The current Total Liabilities is €7.18 Mil. Veru's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Veru (FRA:FMW0), the current Total Liabilities is €7.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veru Business Description

Other Exchanges VERU:USA
Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
32GF Score

Get the complete analysis for FRA:FMW0

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.44
Price